Towards therapeutic vaccines for colorectal carcinoma: A review of clinical trials

Expert Review of Vaccines

Volumn 4, Issue 3, 2005, Pages 329-350

  Mosolits, Szilvia ^a   Nilsson, Bo ^a   Mellstedt, Håkan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Clinical outcome; Colorectal carcinoma; Immune response; Therapy; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EDRECOLOMAB; EPITHELIAL CELL ADHESION MOLECULE; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EP CAM; MUCIN 1; NEWCASTLE DISEASE VACCINE; ONCOVAX; RAS PROTEIN; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; SURVIVIN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON RESECTION; COLORECTAL CARCINOMA; DELAYED HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERANCE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; META ANALYSIS; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VACCINATION;

CANCER VACCINES; CLINICAL TRIALS; COLORECTAL NEOPLASMS; HUMANS; VACCINATION;

EID: 22144433725     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.4.3.329     Document Type: Review

References (136)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IACR Press, Lyon, France (2005).
2. Kerr D. Clinical development of gene therapy for colorectal cancer. Nature Rev. Cancer 3(8), 615-622 (2003).
3. Weitz J, Koch M, Debus J et al. Colorectal cancer. Lancet 365(9454), 153-165 (2005).
4. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur. J. Cancer 58(7), 1000-1015 (2002).
5. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476-487 (2005).
6. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350(23), 2343-2351 (2004).
7. Benson AB, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004).
8. Gray RG, Barnwell J, Hills R et al. QUASAR: A randomized study of adjuvant chemotherapy (CT) vs. observation including 3238 colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 3501 (2004).
9. Andre T, de Gramont A. An overview of adjuvant systemic chemotherapy for colon cancer. Clin. Colorectal Cancer. 4(Suppl.1), S22-S28 (2004).
10. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 3500 (2004).
11. Cassidy J, Scheithauer W, McKendrick J et al. Capecitabine (X) vs. bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a Phase III trial. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 3509 (2004).
12. Chao MW, Tjandra JJ, Gibbs P, McLaughlin S. How safe is adjuvant chemotherapy and radiotherapy for rectal cancer? Asian J. Surg. 27(2), 147-161 (2004).
13. Zampino MG, Labianca R, Beretta G et al. Rectal cancer. Crit. Rev. Oncol. Hematol. 51(2), 121-143 (2004).
14. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nature Rev. Cancer 3(5), 330-338 (2003).
15. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
16. Lenz HJ, Mayer RJ, Gold PJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 3510 (2004).
17. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
18. Gill S, Thomas RR, Goldberg RM. New targeted therapies in gastrointestinal cancers. Curr. Treat. Options Oncol. 4(5), 393-403 (2003).
19. Diaz-Rubio E. New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9(3), 282-294 (2004).
20. Mocellin S, Rossi CR, Lise M, Marincola FM. Adjuvant immunotherapy for solid tumors: from promise to clinical application. Cancer Immunol. Immunother. 51(11-12), 583-595 (2002).
21. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nature Rev. Immunol. 2(4), 227-238 (2002).
22. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002). Important review article discussing the danger model, self and nonself discrimination.
23. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 392(6673), 245-252 (1998).
24. Belardelli F, Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23(4), 201-208 (2002).
25. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Ann. Rev. Immunol. 19, 47-64 (2001). Summarizes aspects of exogenous antigen delivery into the MHC class I processing pathway (cross-presentation).
26. Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumor immunotherapy. Cancer Immunol. Immunother. 51(10), 521-531 (2002).
27. Gilboa E. The promise of cancer vaccines. Nature Rev. Cancer 4(5), 401-411 (2004).
28. Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71(6), 907-920 (2002).
29. + regulatory T-cells for immunologic self-tolerance and negative control of immune responses. Ann. Rev. Immunol. 22, 531-562 (2004).
30. Berzofsky JA, Terabe M, Oh S et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113(11), 1515-1525 (2004). Outlining current vaccine strategies, including a summary of their advantages and disadvantages.
31. Mosolits S, Markovic K, Frodin JE et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin. Cancer Res. 10(16), 5391-5402 (2004).
32. Tartour E, Benchetrit F, Haicheur N, Adotevi O, Fridman WH. Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols. Vaccine 20(Suppl.4), A32-39 (2002).
33. Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23(4), 720-731 (2005). Different cohorts of prime-boost immunization strategy targeting carcinoembyonic antigen.
34. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25(2), 98-104 (2004). Review discussing prime-boost immunization strategy.
35. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21(4), 163-165 (2000).
36. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert. Rev. Vaccines 2(2), 167-188 (2003). Comprehensive overview of vaccine adjuvants.
37. Brewer JM, Conacher M, Hunter CA et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J. Immunol. 163(12), 6448-6454 (1999).
38. Mellstedt H, Fagerberg J, Frodin JE et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr. Opin. Hematol. 6(3), 169-175 (1999).
39. Arina A, Tirapu I, Alfaro C et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells. Exploiting cross-priming. Exp. Hematol. 30(12), 1355-1364 (2002).
40. Klinman DM. CpG DNA as a vaccine adjuvant. Expert. Rev. Vaccines 2(2), 305-315 (2003).
41. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T-cells: March 2004 update. Cancer Immunol. Immunother. 54(3), 187-207 (2005). Comprehensive list of human tumor antigens.
42. Anwar S, Frayling IM, Scott NA, Carlson GL. Systematic review of genetic influences on the prognosis of colorectal cancer. Br. J. Surg. 91(10), 1275-1291 (2004).
43. Gaudernack G, Buanes T, Meo M et al. Clinical trials of a peptide based vaccine targeting telomerase. Proc. Am. Soc. Clin. Oncol. 22, 166 (2003).
44. Dundas SR, Lawrie LC, Rooney PH, Murray GI. Mortalin is overexpressed by colorectal adenocarcinomas and correlates with poor survival. J. Pathol. 205(1), 74-81 (2005).
45. Mosolits S, Harmenberg U, Ruden U et al. Autoantibodies against the tumor-associated antigen GA7332 in patients with colorectal carcinoma. Cancer Immunol. Immunother. 47(6), 315-320 (1999).
46. Nagorsen D, Keilholz U, Rivoltini L et al. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 60(17), 4850-4854 (2000).
47. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit. Rev. Oncol. Hematol. 46(1), 33-57 (2003).
48. Ambe K, Mori M, Enjoji M. S-100 protein-positive dendritic cells in colorectal adenocarcinomas. Distribution and relation to the clinical prognosis. Cancer 63(3), 496-503 (1989).
49. Coca S, Perez-Piqueras J, Martinez D et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 79(12), 2320-2328 (1997).
50. Menon AG, Janssen-van Rhijn CM, Morreau H et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab. Invest. 84(4), 493-501 (2004).
51. + T-cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep. 10(2), 309-313 (2003).
52. + T-cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58(16), 3491-3494 (1998).
53. Nagorsen D, Scheibenbogen C, Letsch A et al. T-cell responses against tumor associated antigens and prognosis in colorectal cancer patients. J. Transl. Med. 3(1), 3 (2005).
54. Albanopoulos K, Armakolas A, Konstadoulakis MM et al. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am. J. Gastroenterol. 95(4), 1056-1061 (2000).
55. Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11(3), 390-399 (1993). Vaccination of colorectal cancer (CRC) patients was shown to be safe during a 6.5-year median follow-up period. Overall survival benefit in colon carcinoma.
56. Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Co-operative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148-157 (2000). First large Phase III vaccine trial in CRC patients. Overall survival benefit in immune responders. Neither serious systemic adverse events nor autoimmune side effects were observed during a median follow-up of 7.6 years.
57. Vermorken JB, Claessen AM, van Tinteren H et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353(9150), 345-350 (1999). Randomized controlled Phase III vaccine trial showing a statistically significant improvement in disease-free survival in Stage II colon cancer. Neither serious systemic adverse events nor autoimmune side effects were observed during a median follow-up of 5.3 years.
58. Hanna MG Jr, Hoover HC Jr, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17-19), 2576-2582 (2001).
59. Liang W, Wang H, Sun TM et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J. Gastroenterol. 9(3), 495-498 (2003). First large randomized controlled Phase III vaccine trial in colon carcinoma demonstrating a statistically significant overall survival benefit in the intent-to-treat population.
60. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al. Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer 84(11), 1443-1446 (2001).
61. Samonigg H, Wilders-Truschnig M, Kuss I et al. A double-blind randomized Phase II trial comparing immunization with anti-idiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J. Immunother. 22(6), 481-488 (1999).
62. Loibner H, Eckert H, Eller N et al. A randomized placebo-controlled Phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2-01). Proc. Am. Soc. Clin. Oncol.. J. Clin. Oncol. 22(14S), 2619 (2004).
63. Riethmuller G, Holz E, Schlimok G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16(5), 1788-1794 (1998).
64. Punt CJ, Nagy A, Douillard JY et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. Lancet 360(9334), 671-677 (2002).
65. Fields AL, Keller AM, Schwartzberg L et al. Edrecolomab (l7-1A antibody) in combination with 5-fluorouracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American Phase III study. Proc. Am. Soc. Clin. Oncol. 21, 128a (2002).
66. Colacchio TA, Niedzwiecki D, Compton C et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc. Am. Soc. Clin. Oncol.. J. Clin. Oncol. 22(14S), 3522 (2004).
67. Habal N, Gupta RK, Bilchik AJ et al. CancerVax®, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann. Surg. Oncol. 8(5), 389-401 (2001).
68. Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2(1), 21-28 (1996).
69. Okinaga K, Iinuma H, Ogiwara T, Ogawa F. A Phase I study of immunotherapy with tumor cell-dendritic cell fusion vaccine in patients with advanced or recurrent gastrointestinal cancer. Proc. Am. Soc. Clin. Oncol.. J. Clin. Oncol. 22(14S), 2615 (2004).
70. Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin. Cancer Res. 9(9), 3235-3245 (2003).
71. Ghanekar SA, Nomura LE, Suni MA et al. Gamma interferon expression in CD8(+) T-cells is a marker for circulating cytotoxic T-lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin. Diagn. Lab. Immunol. 8(3), 628-631 (2001).
72. Liu KJ, Wang CC, Chen LT et al. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 10(8), 2645-2651 (2004).
73. Matsuda K, Tsunoda T, Tanaka H et al. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol. Immunother. 53(7), 609-616 (2004).
74. Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest. 21(3), 341-349 (2003).
75. Ueda Y, Itoh T, Nukaya I et al. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int. J. Oncol. 24(4), 909-917 (2004).
76. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA. 98(15), 8809-8814 (2001). Complete clinical response in 17% of patients after vaccination.
77. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7(8), 2277-2284 (2001).
78. Behrens RJ, Achtar M, Herrin V et al. Phase I/II mutant p53 vaccination in advanced malignancies. Proc. Am. Soc. Clin. Oncol. 22, 186 (2003).
79. Ibrahim RA, Achtar MS, Herrin VE et al. Mutant p53 vaccination of patients with advanced cancers generates specific immunological responses. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 2521 (2004).
80. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63(1), 298-304 (1996).
81. Karanikas V, Thynne G, Mitchell P et al. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection. J. Immunother. 24(2), 172-183 (2001).
82. Mine T, Sato Y, Noguchi M et al. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin. Cancer Res. 10(3), 929-937 (2004).
83. Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 7(12), 3950-3962 (2001).
84. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a β-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. 8(7), 2044-2051 (2002). Analysis of a relatively large number of patients showing association between antibody response and overall survival.
85. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med. 2(1), 19 (2004).
86. Achtar M, Behrens RJ, Herrin V et al. Mutant ras vaccine in advanced cancers. Proc. Am. Soc. Clin. Oncol. 22, 169 (2003).
87. Hamilton J, Behrens RJ, Achtar M et al. An adjuvant Phase II pilot trial of mutant ras peptide vaccine in stage II and III pancreatic and Dukes C and D colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22, 186 (2003).
88. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 17(9), 2889-2885 (1999).
89. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin. Cancer Res. 3(8), 1267-1276 (1997).
90. Basak S, Eck S, Gutzmer R et al. Colorectal cancer vaccines: anti-idiotypic antibody, recombinant protein, and viral vector. Ann. NY Acad. Sci. 910, 237-252; discussion 252-253 (2000).
91. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc. Natl Acad. Sci. USA. 92(11), 4773-4777 (1995).
92. Durrant LG, Buckley DJ, Robins RA, Spendlove I. 105Ad7 cancer vaccine stimulates antitumor helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunizations are required to maintain these responses. Int. J. Cancer 85(1), 87-92 (2000).
93. Durrant LG, Maxwell-Armstrong C, Buckley D et al. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin. Cancer Res. 6(2), 422-430 (2000). No serious adverse events or autoimmune side effects were observed during a median follow-up of 4 years.
94. Amin S, Robins RA, Maxwell-Armstrong CA, Scholefield JH, Durrant LG. Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res. 60(12), 3132-3136 (2000).
95. Samanci A, Yi Q, Fagerberg J et al. Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. Cancer Immunol. Immunother. 47(3), 131-142 (1998).
96. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res. 10(10), 3273-3281 (2004). No serious adverse events or autoimmune side effects were observed during a median follow-up of 6 years.
97. Neidhart J, Allen KO, Barlow DL et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 22(5-6), 773-780 (2004).
98. Staib L, Birebent B, Somasundaram R et al. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int. J. Cancer. 92(1), 79-87 (2001).
99. Reddish MA, MacLean GD, Poppema S, Berg A,Longenecker BM. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42(5), 303-309 (1996).
100. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis Tumor Immunol. 19(1), 59-68 (1996). Analysis of a relatively large number of patients showing association between antibody response and overall survival.
101. Rocha Lima CM, Buck R, Meyer K et al. A multicenter Phase II study of irinotecan in combination with G17DT immunogen in subjects with metastatic colorectal adenocarcinoma (CRC) refractory to previous irinotecan-based chemotherapy. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 3573 (2004).
102. Ullenhag GJ, Frodin JE, Mosolits S et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response. Clin. Cancer Res. 9(7), 2447-2456 (2003).
103. Menon AG, Kuppen PJ, van der Burg SH et al. Safety of intravenous administration of a canarypox virus encoding the human wild type p53 gene in colorectal cancer patients. Cancer Gene Ther. 10(7), 509-517 (2003).
104. Valle JW, Connolly NB, Harrop R et al. Phase I study of escalating doses of TroVax in patients with advanced colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. 22, 181 (2003).
105. Van der Burg SH, Menon AG, Redeker A et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8(5), 1019-1027 (2002).
106. Conry RM, Allen KO, Lee S et al. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. 6(1), 34-41 (2000).
107. Conry RM, Curiel DT, Strong TV et al. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8(9), 2782-2787 (2002).
108. Conry RM, Khazaeli MB, Saleh MN et al. Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. Clin. Cancer Res. 5(9), 2330-2337 (1999).
109. Tsang KY, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T-cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87(13), 982-990 (1995).
110. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anticarcinoembryonic antigen immune responses. J. Clin. Oncol. 18(23), 3964-3973 (2000).
111. Marshall J. Carcinoembryonic antigen-based vaccines. Semin. Oncol. 30(3 Suppl 8), 30-36 (2003).
112. Slack R, Ley L, Chang P et al. Association between CEA-specific T-cell responses (TCR) following treatment with vaccinia-CEA (V) and ALVAC-CEA (A) and survival in patients (Pts) with CEA-bearing cancers. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract No 1086).
113. Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49(9), 504-514 (2000).
114. Von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6(6), 2219-2228 (2000).
115. Von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7(5), 1181-1191 (2001).
116. Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17(1), 332-337 (1999).
117. Morse M, Clay T, Hobeika A et al. Phase I study of immunization with dendritic cells (DC) modified with recombinant fowlpox encoding carcinoembryonic antigen (CEA) and the triad of costimulatory molecules CD54, CD58, and CD80 (rF-CEA(6D)-TRICOM) in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 22(14S), 2508 (2004).
118. LoBuglio AF, Saleh MN, Braddock JM et al. A Phase I trial of humanized antiEGP40 monoclonal antibody 3622W94. Proc. Am. Soc. Clin. Oncol. Abstract No 1562 (1997).
119. Lampkin TA, Khor SP, Saleh MN et al. A Phase I trial of humanized monoclonal antibody 3622W94 including pharmacokinetics (PK) and immunogenicity evaluation. Proc. Am. Soc. Clin. Oncol. (1997) (Abstract No 847).
120. Samonigg H, Hofmann G, Bauernhofer T et al. Phase II trial to explore the influence of concomitant chemotherapy on the immunogenicity of the cancer vaccine IGN101 in patients with epithelial cancers. Proc. Am. Soc. Clin. Oncol. 22, 170 (2003).
121. Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H, Magnusson CG. Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res. 62(5), 1364-1369 (2002).
122. Baral RN, Saha A, Chatterjee SK et al. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. Cancer Immune. Immunother. 52(5), 317-327 (2003).
123. Johnson JR, Williams G, Pazdur R, End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. 21(7), 1404-1411 (2003).
124. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92(3), 205-216 (2000).
125. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin. Cancer Res. 7(5), 1127-1135 (2001).
126. Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 25(2), 97-138 (2002).
127. Basuyau JP, Leroy M, Brunelle P. Determination of tumor markers in serum. Pitfalls and good practice. Clin. Chem. Lab. Med. 39(12), 1227-1233 (2001).
128. Keene SA, Demeure MJ. The clinical significance of micrometastases and molecular metastases. Surgery 129(1), 1-5 (2001).
129. Molnar B, Sipos F, Galamb O, Tulassay Z. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig. Dis. 21(4), 320-325 (2003).
130. Schuster R, Max N, Mann B et al. Quantitative real-time RT-PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int. J. Cancer 108(2), 219-227 (2004).
131. Ko Y, Klinz M, Totzke G et al. Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood. Clin. Cancer Res. 4(9), 2141-2146 (1998).
132. Mariadason JM, Arango D, Augenlicht LH. Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resist. Update 7 (3), 209-218 (2004).
133. Westra JL, Plukker JT, Buys CH, Hofstra RM. Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. Clin. Colorectal Cancer 4(4), 252-259 (2004).
134. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nature Rev. Cancer 5(4), 263-274 (2005). Outlines potential strategies to counteract immune escape mechanisms.
135. Fagerberg J, Hjelm AL, Ragnhammar P et al. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype- reactive T-lymphocytes. Cancer Res. 55(9), 1824-1827 (1995).
136. Tempero MA, MacLean G, Palmer M et al. Theratope® vaccine in metastatic colorectal cancer: immunogenicity and survival in a dose range study. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract No 1005).